{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:50:06Z","timestamp":1767135006406,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd010125","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2014,5,3]],"date-time":"2014-05-03T00:00:00Z","timestamp":1399075200000}}],"reference-count":174,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010125.pub2","type":"journal-article","created":{"date-parts":[[2014,5,3]],"date-time":"2014-05-03T05:19:16Z","timestamp":1399094356000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Aminoadamantanes for chronic hepatitis C"],"prefix":"10.1002","volume":"2014","author":[{"given":"Mieke H","family":"Lamers","sequence":"first","affiliation":[{"name":"Radboud University Medical Center Nijmegen; Department of Gastroenterology and Hepatology; Geert Grooteplein Zuid 10 Nijmegen Netherlands 6525 GA"},{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital; The Cochrane Hepato-Biliary Group; Blegdamsvej 9 Copenhagen Denmark DK-2100"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Broekman","sequence":"additional","affiliation":[{"name":"Radboud University Medical Center Nijmegen; Department of Gastroenterology and Hepatology; Geert Grooteplein Zuid 10 Nijmegen Netherlands 6525 GA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joost PH","family":"Drenth","sequence":"additional","affiliation":[{"name":"Radboud University Medical Center Nijmegen; Department of Gastroenterology and Hepatology; Geert Grooteplein Zuid 10 Nijmegen Netherlands 6525 GA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Gluud","sequence":"additional","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital; The Cochrane Hepato-Biliary Group; Blegdamsvej 9 Copenhagen Denmark DK-2100"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,5,3]]},"reference":[{"key":"10.1002\/14651858.CD010125.pub2-BIB0001|cit1","first-page":"352A","article-title":"Interferon induction plus ribavirin and amantadine as a novel approach for treatment of interferon nonresponder chronic hepatitis C patients","volume":"32","author":"Adinolfi","year":"2000","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0168-8278(00)80745-X","article-title":"High response rates to interferon induction plus ribavirin and amantadine in the treatment of interferon nonresponder chronic hepatitis C patiens: a randomized controlled pilot study","volume":"32","author":"Adinolfi","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD010125.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1136\/gut.52.5.701","article-title":"Effects of alpha interferon induction plus ribavirin with or without amantadine in the treatment of interferon non-responsive chronic hepatitis C: a randomised trial","volume":"52","author":"Adinolfi","year":"2003","journal-title":"Gut"},{"issue":"4","key":"10.1002\/14651858.CD010125.pub2-BIB0004|cit4","first-page":"589A","article-title":"A randomized controlled trial of amantadine plus interferon alpha-2a vs. interferon alpha-2a in naive patients with chronic hepatitis C randomized based on early response to interferon alpha-2a alone","volume":"36","author":"Angelico","year":"2002","journal-title":"Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD010125.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/j.1365-2036.2004.01843.x","article-title":"A randomized controlled trial of amantadine plus interferon-alpha2a vs. interferon-alpha2a alone in naive patients with chronic hepatitis C randomized according to the early virological response to interferon-alpha2a monotherapy","volume":"19","author":"Angelico","year":"2004","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0006|cit6","first-page":"696A","article-title":"Final results of the SMIEC trial in naive patients with hepatitis C: double therapy (peginterferon alfa2a + ribavirin) vs peginterferon monotherapy in early viral responders and vs triple therapy (peginterferon + ribavirin + amantadine) in early non responders","volume":"42","author":"Angelico","year":"2005","journal-title":"Hepatology"},{"issue":"7","key":"10.1002\/14651858.CD010125.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/MEG.0b013e3282f5196c","article-title":"Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naive patients with chronic hepatitis C","volume":"20","author":"Angelico","year":"2008","journal-title":"European Journal of Gastroenterology & Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD010125.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S1386-6346(01)00140-1","article-title":"Amantadine and interferon in the combined treatment of hepatitis C virus in elderly patients","volume":"22","author":"Bacosi","year":"2002","journal-title":"Hepatology Research"},{"issue":"3","key":"10.1002\/14651858.CD010125.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1386-6346(03)00111-6","article-title":"A randomised, open label, controlled trial on the effect of interferon plus amantadine compared with interferon alone for treatment of chronic hepatitis C","volume":"26","author":"Baisini","year":"2003","journal-title":"Hepatology Research"},{"issue":"4","key":"10.1002\/14651858.CD010125.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"A1480","DOI":"10.1016\/S0016-5085(00)81823-5","article-title":"Interferon (IFN) vs interferon + amantadine hydrochloride (IFN+A) for treatment of chronic hepatitis C: an ongoing multicentre randomized trial","volume":"118","author":"Gracielle Pigozzi","year":"2000","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD010125.pub2-BIB0011|cit11","first-page":"338A","article-title":"Interferon (IFN) vs interferon + amantadine (IFN+A) for treatment of chronic hepatitis C: results of a randomised controlled trial","volume":"34","author":"Lanzini","year":"2001","journal-title":"Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD010125.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1053\/jhep.2003.50219","article-title":"Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial","volume":"37","author":"Berg","year":"2003","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0168-8278(02)80002-2","article-title":"Triple therapy with amantadine sulphate plus ribavirin and interferon-alpha in previously untreated patients with chronic hepatitis C: results of a double-blind, placebo-controlled trial","volume":"36","author":"Berg","year":"2002","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0014|cit14","first-page":"330A","article-title":"Randomized, double-blind, placebo-controlled trial of high-dose interferon-alfa induction combination therapy with and without amantadine sulphate in previously untreated patients with chronic hepatitis C","volume":"34","author":"Berg","year":"2001","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/MEG.0b013e3281ac20ca","article-title":"Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-\u03b1 and ribavirin: results from a randomized, placebo-controlled, double-blind trial","volume":"19","author":"Kronenberger","year":"2007","journal-title":"European Journal of Gastroenterology & Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD010125.pub2-BIB0016|cit16","first-page":"130","article-title":"Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders","volume":"31","author":"Brillanti","year":"1999","journal-title":"Italian Journal of Gastroenterology and Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD010125.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1053\/jhep.2000.16235","article-title":"Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C","volume":"32","author":"Brillanti","year":"2000","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0018|cit18","first-page":"704A","article-title":"Does amantadine improve the virological sustained response of naive patients with chronic hepatitis C in association with peg-interferon-ribavirin combination? A prospective, randomised, multicenter, double-blind study: preliminary results in 200 patients","volume":"44","author":"Calay","year":"2005","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"S220","DOI":"10.1016\/S0168-8278(06)80592-1","article-title":"A multicentric, randomized, controlled, double-blind study (TRIPEG): PEGINF \u03b1-2b, ribavirin and amantadine or PEGINF \u03b1-2b, ribavirin and placebo, in 269 naive patients with chronic hepatitis C","volume":"44","author":"Calay","year":"2006","journal-title":"Journal of Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD010125.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S0168-8278(01)00140-4","article-title":"Interferon plus amantadine versus interferon alone in the treatment of naive patients with chronic hepatitis C: a UK multicentre study","volume":"35","author":"Caronia","year":"2001","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0168-8278(00)80756-4","article-title":"Interferon plus amantadine versus interferon alone in the treatment of naive patients with chronic hepatitis C: a UK multicentre study","volume":"32","author":"Caronia","year":"2000","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0022|cit22","first-page":"628A","article-title":"Interferon plus amantadine versus interferon alone in the treatment of naive patients with chronic hepatitis C: interim analysis of multicentre study","volume":"30","author":"Caronia","year":"1999","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0023|cit23","first-page":"138","article-title":"A pilot study of interferon plus amantadine versus interferon alone in the treatment of chronic hepatitis C","volume":"30","author":"Caronia","year":"1999","journal-title":"Journal of Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD010125.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S0168-8278(01)00140-4","article-title":"Interferon plus amantadine versus interferon alone in the treatment of naive patients with chronic hepatitis C: a UK multicentre study","volume":"35","author":"Caronia","year":"2001","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"S148","DOI":"10.1016\/S1386-6532(06)80459-2","article-title":"A randomised trial of pegylated interferon alpha-2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin","volume":"36","author":"Ciancio","year":"2006","journal-title":"Journal of Clinical Virology"},{"issue":"7","key":"10.1002\/14651858.CD010125.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1365-2036.2006.03098.x","article-title":"A randomized trial of pegylated-interferon-alpha2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin","volume":"24","author":"Ciancio","year":"2006","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0027|cit27","first-page":"351A","article-title":"Treatment of chronic hepatitis C in nonresponder patients with high daily induction dosing of interferon-alfa, ribavirin and amantadine\/placebo","volume":"21","author":"Cornberg","year":"2000","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0168-8278(04)90476-X","article-title":"Prospective evaluation of the 24 hour interferon (IFN) induced decline in hepatitis C virus genotype 1 load to predict sustained virologic response (SVR) to peginterferon-alfa2a\/ribavirin combination therapy with or without amantadine","volume":"40","author":"Ferenci","year":"2004","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0029|cit29","first-page":"396A","article-title":"Randomized, controlled, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) (Pegasys\u00ae) plus ribavirin (Copegus\u00ae) and amantadine (AMA) or placebo in patients with chronic hepatitis C genotype 1 infection","volume":"40","author":"Ferenci","year":"2004","journal-title":"Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD010125.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jhep.2005.09.015","article-title":"Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naive patients with chronic hepatitis C genotype 1 infection","volume":"44","author":"Ferenci","year":"2006","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0031|cit31","first-page":"338A","article-title":"Effect of amantadine on quality of life and fatigue in patients with chronic hepatitis C participating in a prospective, double blind, placebo controlled, randomized trial of treatment with pegylated interferon alfa2a\/ribavirin","volume":"40","author":"Formann","year":"2004","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0032|cit32","first-page":"632A","article-title":"Interferon alfa-2a (IFN) plus amantadine in chronic hepatitis C resistant to IFN-\u03b1 alone: a pilot randomised study","volume":"30","author":"Gaeta","year":"1999","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD010125.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1046\/j.1365-2893.2001.00298.x","article-title":"Interferon-alpha plus amantadine in chronic hepatitis C resistant to interferon alone: a pilot randomized study","volume":"8","author":"Gaeta","year":"2001","journal-title":"Journal of Viral Hepatitis"},{"issue":"S2","key":"10.1002\/14651858.CD010125.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0168-8278(03)80691-8","article-title":"IFN plus ribavirin and amantadine for IFN-sensitive patients with chronic hepatitis C: results of a multicenter, randomized, controlled trial","volume":"38","author":"Andreone","year":"2003","journal-title":"Journal of Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD010125.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s00535-007-2006-3","article-title":"A randomized trial of induction doses of interferon alone or in combination with ribavirin or ribavirin plus amantadine for treatment of nonresponder patients with chronic hepatitis C","volume":"42","author":"Gramenzi","year":"2007","journal-title":"Journal of Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD010125.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1177\/135965350400900409","article-title":"Peginterferon alpha-2b plus ribavirin with or without amantadine [correction of amantidine] for the treatment of non-responders to standard interferon and ribavirin","volume":"9","author":"Hasan","year":"2004","journal-title":"Antiviral Therapy"},{"issue":"4","key":"10.1002\/14651858.CD010125.pub2-BIB0037|cit37","first-page":"331A","article-title":"Interferon alfa-2a (IFN) and amantadine (A) or placebo (P) in IFN-naive patients with chronic hepatitis C (CHC): a double-blind, randomized, placebo-controlled trial","volume":"34","author":"Helbling","year":"2001","journal-title":"Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD010125.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1053\/jhep.2002.31168","article-title":"Interferon and amantadine in naive chronic hepatitis C: a double-blind, randomized, placebo-controlled trial","volume":"35","author":"Helbling","year":"2002","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD010125.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s10620-005-2563-3","article-title":"Peginterferon alpha-2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha-2b plus ribavirin: a pilot study of efficacy and safety","volume":"50","author":"Herrine","year":"2005","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0040|cit40","first-page":"156","article-title":"Interferon induction treatment with and without amantadine HCl (AHCl) in patients with chronic hepatitis C","volume":"34","author":"Jorge","year":"2001","journal-title":"Journal of Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD010125.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2036.2009.04052.x","article-title":"Clinical trial: a randomized trial of pegylated-interferon-alpha-2a plus ribavirin with or without amantadine in treatment-naive or relapsing chronic hepatitis C patients","volume":"30","author":"Langlet","year":"2009","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD010125.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1053\/jhep.2001.23537","article-title":"A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C","volume":"33","author":"Mangia","year":"2001","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0043|cit43","first-page":"318A","article-title":"Long term response to amantadine + interferon is significantly higher than that to interferon alone in chronic hepatitis C: final report of a randomized clinical trial","volume":"32","author":"Mangia","year":"2000","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0044|cit44","first-page":"398A","article-title":"Retreatment of IFN\/ribavirin non-responder hepatitis C patients: benefit of peg-interferon\/ribavirin\/amantadine","volume":"40","author":"Maynard","year":"2004","journal-title":"Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD010125.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jhep.2005.11.038","article-title":"Amantadine triple therapy for non-responder hepatitis C patients. Clues for controversies (ANRS HC 03 BITRI)","volume":"44","author":"Maynard","year":"2006","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0046|cit46","first-page":"707A","article-title":"Assessment and prediction of sustained virological response among treatment-naive Latinos with, genotype 1 HCV treated with standard double versus triple therapy with amantadine","volume":"50","author":"Mendez-Navarro","year":"2009","journal-title":"Hepatology"},{"issue":"9","key":"10.1002\/14651858.CD010125.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1007\/s10620-009-1062-3","article-title":"A randomized controlled trial of double versus triple therapy with amantadine for genotype 1 chronic hepatitis C in Latino patients","volume":"55","author":"Mendez-Navarro","year":"2010","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"S209","DOI":"10.1016\/S0168-8278(06)80562-3","article-title":"Prospective randomized study of peginterferon alpha-2a plus ribavirin, in hepatitis C patients non-responders or relapsers to interferon-alpha and ribavirin","volume":"44","author":"Cheinquer","year":"2006","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD010125.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S1665-2681(19)31486-3","article-title":"Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin +\/- amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial","volume":"11","author":"Pessoa","year":"2012","journal-title":"Annals of Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD010125.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S1386-6346(03)00015-9","article-title":"Triple (interferon, ribavirin, amantadine) versus double (interferon, ribavirin) re-therapy for interferon relapser genotype 1b HCV chronic active hepatitis patients","volume":"25","author":"Piai","year":"2003","journal-title":"Hepatology Research"},{"issue":"2","key":"10.1002\/14651858.CD010125.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1365-2893.2006.00771.x","article-title":"Induction doses of interferon-alpha-2a in combination with ribavirin and\/or amantadine for the treatment of chronic hepatitis C in non-responders to interferon monotherapy: a randomized trial","volume":"14","author":"Salmeron","year":"2007","journal-title":"Journal of Viral Hepatitis"},{"issue":"5","key":"10.1002\/14651858.CD010125.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s15010-001-2045-2","article-title":"Pilot study of interferon-alpha with and without amantadine for the treatment of hepatitis C in HIV coinfected individuals on antiretroviral therapy","volume":"29","author":"Sax","year":"2001","journal-title":"Infection"},{"issue":"7","key":"10.1002\/14651858.CD010125.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1023\/A:1015804227191","article-title":"A randomized, double-blind, placebo-controlled trial of interferon-alpha and amantadine versus interferon-alpha alone in the treatment of patients with chronic hepatitis C","volume":"47","author":"Ahmad","year":"2002","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"A1487","DOI":"10.1016\/S0016-5085(00)81853-3","article-title":"A randomized, double-blind, placebo controlled trial of interferon-alfa and amantadine versus interferon-alfa alone in the treatment of chronic hepatitis C","volume":"118","author":"Shakil","year":"2000","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD010125.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/j.1525-1497.2004.30057.x","article-title":"Amantadine therapy for chronic hepatitis C","volume":"19","author":"Smith","year":"2004","journal-title":"Journal of General Internal Medicine"},{"issue":"S4","key":"10.1002\/14651858.CD010125.pub2-BIB0056|cit56","first-page":"A","article-title":"Amantadine therapy for chronic hepatitis C: a randomized double-blind placebo controlled trial","volume":"122","author":"Smith","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0057|cit57","first-page":"628A","article-title":"Combination therapy interferon plus amantadine in chronic active hepatitis C. A multicentric randomised study: preliminary reports","volume":"30","author":"Tabone","year":"1999","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD010125.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0168-8278(01)00166-0","article-title":"Interferon and amantadine in combination as initial treatment for chronic hepatitis C patients","volume":"35","author":"Tabone","year":"2001","journal-title":"Journal of Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD010125.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1046\/j.1365-2893.2001.00297.x","article-title":"Randomized, placebo-controlled, double-blind trial with interferon-alpha with and without amantadine sulphate in primary interferon-alpha nonresponders with chronic hepatitis C","volume":"8","author":"Teuber","year":"2001","journal-title":"Journal of Viral Hepatitis"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0060|cit60","first-page":"354A","article-title":"Randomized, placebo-controlled, double-blind trial with interferon-A (IFN A) with and without amantadin-sulfat in primary IFN-A non-responders with chronic hepatitis C","volume":"32","author":"Teuber","year":"2000","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"A1494","DOI":"10.1016\/S0016-5085(00)81881-8","article-title":"Multicenter, randomized, double-blind, placebo-controlled trial of interferon-A (IFN-A2A) with and without amantadine as treatment for IFN-A non-responders with chronic hepatitis C","volume":"118","author":"Teuber","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0062|cit62","first-page":"579A","article-title":"Randomized, controlled trial with interferon-alfa plus ribavirin with and without amantadine sulphate in patients with chronic hepatitis C relapsing after primary successful antiviral treatment","volume":"34","author":"Teuber","year":"2001","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0168-8278(02)80472-X","article-title":"Randomized, controlled trial with interferon-alpha plus ribavirin with and without amantadine sulphate in patients with chronic hepatitis C relapsing after previous successful antiviral treatment","volume":"36","author":"Teuber","year":"2002","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD010125.pub2-BIB0065|cit64","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0168-8278(01)80069-6","article-title":"Randomized, controlled trial with interferon-alpha (IFN-alpha) combined with ribavirin with and without amantadine sulfate in primary IFN-alpha nonresponsive patients with chronic hepatitis C","volume":"34","author":"Teuber","year":"2001","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0064|cit65","first-page":"A381","article-title":"Randomized, controlled trial with interferon-\u03b1 (IFN-\u03b1) combined with ribavirin with and without amantadinsulfat in primary IFN-\u03b1 non-responders with chronic hepatitis C","volume":"120","author":"Teuber","year":"2001","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD010125.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0168-8278(03)00298-8","article-title":"Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C","volume":"39","author":"Teuber","year":"2003","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD010125.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1136\/gut.53.1.130","article-title":"Randomised, double blind, placebo controlled trial of interferon, ribavirin, and amantadine versus interferon, ribavirin, and placebo in treatment naive patients with chronic hepatitis C","volume":"53","author":"Thuluvath","year":"2004","journal-title":"Gut"},{"issue":"7","key":"10.1002\/14651858.CD010125.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.dld.2009.10.006","article-title":"No beneficial effects of amantadine in treatment of chronic hepatitis C patients","volume":"42","author":"Soest","year":"2010","journal-title":"Digestive and Liver Disease"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S0168-8278(01)80652-8","article-title":"Interferon plus amantadine has no superiority to IFN monotherapy in naive patients with chronic hepatitis C","volume":"34","author":"Vardar","year":"2001","journal-title":"Journal of Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD010125.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/hep.22483","article-title":"Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection","volume":"48","author":"Wagner","year":"2008","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0071|cit71","first-page":"342A","article-title":"Randomized, double-blind, placebo-controlled trial of peginterferon alfa-2a (40KD) and ribavirin with and without 400 mg amantadine-sulphate for 48 weeks in treatment naive HCV genotype 1-infected patients","volume":"46","author":"Wagner","year":"2007","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0072|cit72","first-page":"886A","article-title":"Sustained virologic response is associated with worse QoL during and improved QoL after treatment with peginterferon alfa-2a and ribavirin","volume":"48","author":"Wagner","year":"2008","journal-title":"Hepatology"},{"issue":"29-30","key":"10.1002\/14651858.CD010125.pub2-BIB0073|cit73","first-page":"418","article-title":"Interferon and ribavirin with or without amantadine for interferon non-responders with chronic hepatitis C. A randomized, controlled pilot study","volume":"137","author":"Wenger","year":"2007","journal-title":"Swiss Medical Weekly"},{"issue":"53","key":"10.1002\/14651858.CD010125.pub2-BIB0074|cit74","first-page":"1575","article-title":"Combination of interferon alfa-2a and amantadine does not improve the efficacy of interferon therapy in patients with chronic hepatitis C","volume":"50","author":"Yang","year":"2003","journal-title":"Hepato-Gastroenterology"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0075|cit75","first-page":"369A","article-title":"Combination of interferon alfa-2a and amantadine does not improve the efficacy of interferon therapy in patients with chronic hepatitis C","volume":"30","author":"Yang","year":"1999","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0076|cit76","first-page":"200A","article-title":"Randomised, double-blind, placebo-controlled trial of interferon-alfa with and without amantadine as initial treatment for chronic hepatitis C","volume":"30","author":"Zeuzem","year":"1999","journal-title":"Hepatology"},{"issue":"4 Pt 1","key":"10.1002\/14651858.CD010125.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1053\/jhep.2000.17740","article-title":"Randomized, double-blind, placebo-controlled trial of interferon alfa2a with and without amantadine as initial treatment for chronic hepatitis C","volume":"32","author":"Zeuzem","year":"2000","journal-title":"Hepatology"},{"issue":"S1","key":"10.1002\/14651858.CD010125.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"S382","DOI":"10.1016\/S0168-8278(09)61052-7","article-title":"Treating relapse with peginterferon alfa-2a plus ribavirin and amantadin for either 72 or 48 weeks (in patients with HDV-type 1\/3 infection): results from the TRELA-study","volume":"50","author":"Buggisch","year":"2009","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0168-8278(01)80523-7","article-title":"Pegylated (40 KDA) interferon alfa-2a (Pegasys\u00ae) in new combination therapies: a report of a randomized, multicenter efficacy and safety study","volume":"34","author":"Bisceglie","year":"2001","journal-title":"Journal of Hepatology"},{"issue":"10","key":"10.1002\/14651858.CD010125.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1007\/s10620-009-1114-8","article-title":"Erratum: a randomized controlled trial of double versus triple therapy with amantadine for genotype 1 chronic hepatitis C in Latino patients","volume":"55","author":"Mendez-Navarro","year":"2010","journal-title":"Digestive Diseases and Sciences"},{"issue":"49","key":"10.1002\/14651858.CD010125.pub2-BIB0081|cit81","first-page":"222","article-title":"The combination therapy of interferon and amantadine hydrochloride for patients with chronic hepatitis C","volume":"50","author":"Nakamura","year":"2003","journal-title":"Hepato-Gastroenterology"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0082|cit82","doi-asserted-by":"crossref","unstructured":"Popovic A Vian A Lorenzoni U Lobello S Pevere S Silverij E Daily interferon monotherapy versus daily interferon plus amantadine in the treatment of naive chronic hepatitis C patients: short-term response Journal of Hepatology 2000 195","DOI":"10.1016\/S0168-8278(00)81077-6"},{"issue":"3","key":"10.1002\/14651858.CD010125.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/01.WNF.0000220824.57769.E5","article-title":"Effect of amantadine on depressive symptoms in chronic hepatitis C patients treated with pegylated interferon: a randomized, controlled pilot study","volume":"29","author":"Quarantini","year":"2006","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0168-8278(03)80832-2","article-title":"Randomized placebo controlled double blind study in patients with chronic hepatitis C who did not respond to interferon therapy: comparison between interferon A, ribavirin +\/- amantadine","volume":"38","author":"Schories","year":"2003","journal-title":"Journal of Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD010125.pub2-BIB0085|cit85","first-page":"572A","article-title":"Randomized placebo controlled double blind study in interferon nonresponder chronic hepatitis C patients with interferon A, ribavirin, amantadine in comparison to interferon A and ribavirin","volume":"36","author":"Schories","year":"2002","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0086|cit86","first-page":"128","article-title":"HCV-RNA dynamics in the first month of treatment with IFN daily therapy alone versus combinations with amantadine or ribavirin","volume":"30","author":"Torre","year":"1999","journal-title":"Journal of Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD010125.pub2-BIB0087|cit87","first-page":"149","article-title":"Triple antiviral re-therapy for chronic hepatitis C with interferon-alpha, ribavirin and amantadine in nonresponders to interferon-alpha and ribavirin","volume":"7","author":"Zilly","year":"2002","journal-title":"European Journal of Medical Research"},{"issue":"7382","key":"10.1002\/14651858.CD010125.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/bmj.326.7382.219","article-title":"Interaction revisited: the difference between two estimates","volume":"326","author":"Altman","year":"2003","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"1","key":"10.1002\/14651858.CD010125.pub2-BIB0089|cit89","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002745.pub3","article-title":"Amantadine and rimantadine for influenza A in children and the elderly","author":"Alves Galv\u00e3o","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD010125.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1111\/j.1478-3231.2010.02283.x","article-title":"Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin","volume":"30","author":"Asselah","year":"2010","journal-title":"Liver International"},{"issue":"4","key":"10.1002\/14651858.CD010125.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/hep.23504","article-title":"Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials","volume":"51","author":"Awad","year":"2010","journal-title":"Hepatology"},{"issue":"13","key":"10.1002\/14651858.CD010125.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD010125.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jclinepi.2007.10.007","article-title":"Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses","volume":"61","author":"Brok","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD010125.pub2-BIB0094|cit94","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005527.pub2","article-title":"Ribavirin monotherapy for chronic hepatitis C","author":"Brok","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD010125.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/ije\/dyn188","article-title":"Apparently conclusive meta-analyses may be inconclusive - Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses","volume":"38","author":"Brok","year":"2009","journal-title":"International Journal of Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD010125.pub2-BIB0096|cit96","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005445.pub2","article-title":"Ribavirin plus interferon versus interferon for chronic hepatitis C","author":"Brok","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD010125.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"e748","DOI":"10.1016\/j.ijid.2012.06.002","article-title":"Meta-analysis: amantadine may lower the efficacy of pegylated interferon plus ribavirin in treatment-naive hepatitis C genotype 1 patients","volume":"16","author":"Chen","year":"2012","journal-title":"International Journal of Infectious Diseases"},{"issue":"4902","key":"10.1002\/14651858.CD010125.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1126\/science.2523562","article-title":"Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome","volume":"244","author":"Choo","year":"1989","journal-title":"Science"},{"issue":"Suppl","key":"10.1002\/14651858.CD010125.pub2-BIB0099|cit99","first-page":"E156","article-title":"Adverse effects and other safety aspects of the hepatitis C antivirals","volume":"15","author":"Chutaputti","year":"2000","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD010125.pub2-BIB0100|cit100","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003468","article-title":"Amantadine in Parkinson's disease","author":"Crosby","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0101|cit101","unstructured":"Copenhagen Trial Unit TSA - Trial Sequential Analysis ctu.dk\/tsa\/"},{"issue":"22","key":"10.1002\/14651858.CD010125.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1056\/NEJM198911303212203","article-title":"Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group","volume":"321","author":"Davis","year":"1989","journal-title":"New England Journal of Medicine"},{"issue":"21","key":"10.1002\/14651858.CD010125.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1056\/NEJM199811193392102","article-title":"Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group","volume":"339","author":"Davis","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD010125.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S1386-6532(01)00167-6","article-title":"Antiviral drugs: current state of the art","volume":"22","author":"Clercq","year":"2001","journal-title":"Journal of Clinical Virology"},{"issue":"3","key":"10.1002\/14651858.CD010125.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jhep.2004.05.019","article-title":"Evaluation of amantadine in chronic hepatitis C: a meta-analysis","volume":"41","author":"Deltenre","year":"2004","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD010125.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/sim.4780060325","article-title":"Methods for combining randomised clinical trials: strengths and limitations","volume":"6","author":"DeMets","year":"1987","journal-title":"Statistics in Medicine"},{"issue":"3","key":"10.1002\/14651858.CD010125.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"issue":"4","key":"10.1002\/14651858.CD010125.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1002\/hep.24169","article-title":"Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon","volume":"53","author":"Bisceglie","year":"2011","journal-title":"Hepatology"},{"issue":"7","key":"10.1002\/14651858.CD010125.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1365-2893.2011.01476.x","article-title":"Long-term outcome of chronic hepatitis C in a population-based cohort and impact of antiviral therapy: a propensity-adjusted analysis","volume":"18","author":"Martino","year":"2011","journal-title":"Journal of Viral Hepatitis"},{"issue":"2","key":"10.1002\/14651858.CD010125.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2011.02.023","article-title":"EASL Clinical Practice Guidelines: management of hepatitis C virus infection","volume":"55","author":"European Association for the Study of the Liver","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"7109","key":"10.1002\/14651858.CD010125.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"1","key":"10.1002\/14651858.CD010125.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta7010","article-title":"How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study","volume":"7","author":"Egger","year":"2003","journal-title":"Health Technology Assessment"},{"issue":"10","key":"10.1002\/14651858.CD010125.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"817","DOI":"10.7326\/0003-4819-139-10-200311180-00009","article-title":"The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update","volume":"139","author":"El-Serag","year":"2003","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD010125.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management, and treatment of hepatitis C: an update","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD010125.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0168-8278(98)80021-4","article-title":"Quality assessment of reports on clinical trials in the Journal of Hepatology","volume":"29","author":"Gluud","year":"1998","journal-title":"Journal of Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD010125.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jhep.2007.01.003","article-title":"Hepatology may have problems with putative surrogate outcome measures","volume":"46","author":"Gluud","year":"2007","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0117|cit117","doi-asserted-by":"crossref","unstructured":"Gluud C Nikolova D Klingenberg SL Alexakis N Als-Nielsen B Colli A Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2014, Issue 1. Art. No.: LIVER","DOI":"10.1002\/14651858.CD009182.pub2"},{"issue":"12","key":"10.1002\/14651858.CD010125.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"e83313","DOI":"10.1371\/journal.pone.0083313","article-title":"Is sustained virological response a marker of treatment efficacy in patients with chronic hepatitis C viral infection with no response or relapse to previous antiviral intervention?","volume":"8","author":"Gurusamy","year":"2013","journal-title":"PloS One"},{"issue":"7650","key":"10.1002\/14651858.CD010125.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"2","key":"10.1002\/14651858.CD010125.pub2-BIB0120|cit120","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005441.pub3","article-title":"Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C","author":"Hauser","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD010125.pub2-BIB0121|cit121","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005642.pub3","article-title":"Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C","author":"Hauser","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD010125.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0123|cit123","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"issue":"7211","key":"10.1002\/14651858.CD010125.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1136\/bmj.319.7211.670","article-title":"What is meant by intention to treat analysis? Survey of published randomised controlled trials","volume":"319","author":"Hollis","year":"1999","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0125|cit125","volume-title":"International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice 1997 CFR & ICH Guidelines","volume":"1","author":"International Conference on Harmonisation Expert Working Group","year":"1997"},{"issue":"25","key":"10.1002\/14651858.CD010125.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD010125.pub2-BIB0127|cit127","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001169.pub3","article-title":"Amantadine and rimantadine for influenza A in adults","author":"Jefferson","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"16","key":"10.1002\/14651858.CD010125.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJM199904223401602","article-title":"Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group","volume":"340","author":"Kenny-Walsh","year":"1999","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD010125.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1053\/j.gastro.2009.07.047","article-title":"Trends in waiting list registration for liver transplantation for viral hepatitis in the United States","volume":"137","author":"Kim","year":"2009","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD010125.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1002\/hep.510300510","article-title":"Randomized clinical trials in HEPATOLOGY: predictors of quality","volume":"30","author":"Kjaergard","year":"1999","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"982","DOI":"10.7326\/0003-4819-135-11-200112040-00010","article-title":"Reported methodologic quality and discrepancies between large and small randomised trials in meta-analyses","volume":"135","author":"Kjaergard","year":"2001","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD010125.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1128\/AAC.18.1.125","article-title":"Inhibition of dengue virus replication by amantadine hydrochloride","volume":"18","author":"Koff","year":"1980","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"2","key":"10.1002\/14651858.CD010125.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"110","DOI":"10.7326\/0003-4819-119-2-199307150-00003","article-title":"Non-A, non-B post-transfusion hepatitis. Looking back in the second decade","volume":"119","author":"Koretz","year":"1993","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD010125.pub2-BIB0134|cit134","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003617.pub2","article-title":"Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C","author":"Koretz","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD010125.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJM200107053450107","article-title":"Hepatitis C virus infection","volume":"345","author":"Lauer","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD010125.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1469-0691.2010.03432.x","article-title":"Evolving epidemiology of hepatitis C virus","volume":"17","author":"Lavanchy","year":"2011","journal-title":"Clinical Microbiology and Infection"},{"issue":"5","key":"10.1002\/14651858.CD010125.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1365-2893.2005.00622.x","article-title":"Amantadine in treatment of chronic hepatitis C virus infection?","volume":"12","author":"Lim","year":"2005","journal-title":"Journal of Viral Hepatitis"},{"issue":"12","key":"10.1002\/14651858.CD010125.pub2-BIB0138|cit138","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000033.pub2","article-title":"Industry sponsorship and research outcome","author":"Lundh","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"21","key":"10.1002\/14651858.CD010125.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","article-title":"Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group","volume":"339","author":"McHutchison","year":"1998","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","article-title":"Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?","volume":"352","author":"Moher","year":"1998","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD010125.pub2-BIB0141|cit141","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000370","article-title":"Interferon for interferon naive patients with chronic hepatitis C","author":"Myers","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD010125.pub2-BIB0142|cit142","first-page":"207","article-title":"CONSORT. Consolidated Standards of Reporting Trials","volume":"186","author":"Needleman","year":"1999","journal-title":"British Dental Journal"},{"issue":"13","key":"10.1002\/14651858.CD010125.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"9138","key":"10.1002\/14651858.CD010125.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S0140-6736(98)07124-4","article-title":"Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)","volume":"352","author":"Poynard","year":"1998","journal-title":"Lancet"},{"issue":"8749","key":"10.1002\/14651858.CD010125.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/0140-6736(91)91707-2","article-title":"Ribavirin treatment for chronic hepatitis C","volume":"337","author":"Reichard","year":"1991","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD010125.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/jmv.1890410203","article-title":"Hepatitis C viral RNA titers in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis C","volume":"41","author":"Reichard","year":"1993","journal-title":"Journal of Medical Virology"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0147|cit147","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2012"},{"issue":"3","key":"10.1002\/14651858.CD010125.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1053\/jhep.2000.9714","article-title":"Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975","volume":"32","author":"Rodger","year":"2000","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD010125.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1017\/S0266462303000552","article-title":"Literature searching for randomised controlled trials used in Cochrane reviews: rapid versus exhaustive searches","volume":"19","author":"Royle","year":"2003","journal-title":"International Journal of Technology Assessment in Health Care"},{"issue":"35","key":"10.1002\/14651858.CD010125.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta16350","article-title":"Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials","volume":"16","author":"Savovi\u0107","year":"2012","journal-title":"Health Technology Assessment"},{"issue":"6","key":"10.1002\/14651858.CD010125.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"429","DOI":"10.7326\/0003-4819-157-6-201209180-00537","article-title":"Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials","volume":"157","author":"Savovi\u0107","year":"2012","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schultz","year":"1995","journal-title":"JAMA"},{"issue":"8","key":"10.1002\/14651858.CD010125.pub2-BIB0153|cit153","first-page":"672","article-title":"CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials","volume":"9","author":"Schulz","year":"2011","journal-title":"Internal Journal of Surgery"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010125.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1478-3231.2008.01927.x","article-title":"The history of the \"natural history\" of hepatitis C (1968-2009)","volume":"29","author":"Seeff","year":"2009","journal-title":"Liver International"},{"issue":"11","key":"10.1002\/14651858.CD010125.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1056\/NEJMoa1014463","article-title":"Response-guided telaprevir combination treatment for hepatitis C virus infection","volume":"365","author":"Sherman","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD010125.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1365-2036.2007.03294.x","article-title":"Cochrane systematic review: pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C","volume":"25","author":"Simin","year":"2007","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD010125.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/hep.20819","article-title":"Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes","volume":"42","author":"Simmonds","year":"2005","journal-title":"Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD010125.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/j.1572-0241.2004.30798.x","article-title":"Amantadine therapy for chronic hepatitis C: a dose escalation study","volume":"99","author":"Smith","year":"2004","journal-title":"American Journal of Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD010125.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1053\/jhep.2002.36502","article-title":"Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C","volume":"36","author":"Soza","year":"2002","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","article-title":"SPIRIT 2013 Statement: defining standard protocol items for clinical trials","volume":"158","author":"Chan","year":"2013","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0161|cit161","first-page":"e7586","article-title":"SPIRIT 2013 Explanation and Elaboration: Guidance for protocols of clinical trials","volume":"346","author":"Chan","year":"2013","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"3","key":"10.1002\/14651858.CD010125.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1365-2893.2004.00490.x","article-title":"Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection","volume":"11","author":"Sulkowski","year":"2004","journal-title":"Journal of Viral Hepatitis"},{"issue":"2","key":"10.1002\/14651858.CD010125.pub2-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"41","DOI":"10.7150\/ijms.3.41","article-title":"Epidemiology of hepatitis C virus (HCV) infection","volume":"3","author":"Sy","year":"2006","journal-title":"International Journal of Medical Sciences"},{"issue":"2","key":"10.1002\/14651858.CD010125.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/hep.22375","article-title":"Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression","volume":"48","author":"Thein","year":"2008","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD010125.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/ije\/dyn179","article-title":"Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses","volume":"38","author":"Thorlund","year":"2009","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0166|cit166","first-page":"57","article-title":"Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals","volume":"2","author":"Thorlund","year":"2010","journal-title":"Clinical Epidemiology"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0167|cit167","unstructured":"Thorlund K Engstr\u00f8m J Wetterslev J Brok J Imberger G Gluud C User manual for Trial Sequential Analysis (TSA) ctu.dk\/tsa\/files\/tsa_manual.pdf"},{"issue":"2","key":"10.1002\/14651858.CD010125.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/0168-8278(91)90814-R","article-title":"Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomised clinical trials","volume":"13","author":"Tine","year":"1991","journal-title":"Journal of Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD010125.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1440-1746.2009.05814.x","article-title":"Prevention of hepatocellular carcinoma complicating chronic hepatitis C","volume":"24","author":"Ueno","year":"2009","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD010125.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","article-title":"Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis","volume":"61","author":"Wetterslev","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD010125.pub2-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1471-2288-9-86","article-title":"Estimating required information size by quantifying diversity in random effects model meta-analyses","volume":"9","author":"Wetterslev","year":"2009","journal-title":"BMC Medical Research Methodology"},{"issue":"1","key":"10.1002\/14651858.CD010125.pub2-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/jhep.2000.8169","article-title":"Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study","volume":"32","author":"Wiese","year":"2000","journal-title":"Hepatology"},{"issue":"7644","key":"10.1002\/14651858.CD010125.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","article-title":"Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study","volume":"336","author":"Wood","year":"2008","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"25","key":"10.1002\/14651858.CD010125.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"New England Journal of Medicine"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD010125.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,26]],"date-time":"2024-05-26T05:26:20Z","timestamp":1716701180000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD010125.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Hepato-Biliary Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,5,3]]},"references-count":174,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2014,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010125.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,3]]}}}